Zobrazeno 1 - 10
of 53
pro vyhledávání: '"R T, Schooley"'
Autor:
Stephanie, LaVergne, Theron, Hamilton, Biswajit, Biswas, M, Kumaraswamy, R T, Schooley, Darcy, Wooten
Publikováno v:
Open Forum Infectious Diseases
In the era of antibiotic resistance, alternative treatment options for multidrug-resistant bacterial infections are being explored. We present a case of multidrug-resistant Acinetobacter baumannii infection treated with bacteriophages. Clinical trial
Autor:
N H, Afdhal, S, Zeuzem, R T, Schooley, D L, Thomas, J W, Ward, A H, Litwin, H, Razavi, L, Castera, T, Poynard, A, Muir, S H, Mehta, L, Dee, C, Graham, D R, Church, A H, Talal, M S, Sulkowski, I M, Jacobson, Stefan, Zeuzem
Publikováno v:
Journal of Viral Hepatitis
SUMMARY. Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effect
Publikováno v:
The Journal of Immunology. 147:2368-2376
Two different approaches were used to map the type-specific regions on human T cell leukemia virus (HTLV) envelope glycoproteins. 1) Antibody reactivities of polymerase chain reaction-confirmed HTLV-I or HTLV-II carriers' sera were analyzed by Wester
Autor:
R T, Schooley, N, Clumeck, R, Haubrich, M, Thompson, S A, Danner, M E, van Der Ende, D, Sereni, F, Antunes, D, Blake, R E, Myers, M, Tisdale, J, Millard, N, Mustafa, P, Nacci
Publikováno v:
Antiviral therapy. 6(2)
To evaluate the antiretroviral activity and safety of multiple escalating doses of amprenavir administered alone, and in combination with abacavir in HIV-1-infected adults.Sixty-two HIV-1-infected subjects were enrolled in a multicentre, open-label,
Autor:
W J, Burman, R T, Schooley
Publikováno v:
JAMA. 285(21)
Autor:
T B, Campbell, A, Sevin, R W, Coombs, G C, Peterson, M, Rosandich, D R, Kuritzkes, J, Mladenovic, A, Landay, R, Wong, D, Ambruso, S, Miles, R J, Pomerantz, R T, Schooley
Publikováno v:
Blood. 95(1)
Genetic modification of hemopoietic progenitor cells ex vivo, followed by the infusion of the genetically modified cells into the human immunodeficiency virus-1 (HIV-1) infected donor, has been proposed as a treatment for HIV-1 infection. The current
Autor:
M S, Saag, A, Sonnerborg, R A, Torres, D, Lancaster, B G, Gazzard, R T, Schooley, C, Romero, D, Kelleher, W, Spreen, S, LaFon
Publikováno v:
AIDS (London, England). 12(16)
To evaluate, over 12 weeks, the antiretroviral activity and safety of abacavir, used alone and in combination with zidovudine (ZDV), as treatment for HIV-1-infected subjects who had limited or no antiretroviral treatment.Seventy-nine HIV-1-infected s
Autor:
M S, Saag, R T, Schooley
Publikováno v:
Current clinical topics in infectious diseases. 18
Autor:
R T, Mitsuyasu, P R, Skolnik, S R, Cohen, B, Conway, M J, Gill, P C, Jensen, J J, Pulvirenti, L N, Slater, R T, Schooley, M A, Thompson, R A, Torres, C M, Tsoukas
Publikováno v:
AIDS (London, England). 12(11)
A Phase II, open-label, randomized, parallel-arm, multicentre trial to compare the antiviral activity and safety of two formulations of saquinavir (SQV), soft gelatin (SQV-SGC) and hard gelatin (SQV-HGC) capsules, in combination with two nucleoside r
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 161(1)
We studied the in vitro effects of IL-12 on HIV-1-specific CTL lines derived from PBMC of HIV-1-infected children. HIV-1-specific CTL lines were derived by limiting dilution following Ag-specific stimulation of PBMC from HIV-1-infected children and w